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ABSTRACT 
For over 80 years, cystoscopy has remained the gold-standard for detecting tumours of the 
urinary bladder.  Since bladder tumours have a tendency to recur and progress, many 
patients are subjected to repeated cystoscopies during long-term surveillance, with the 
procedure being both unpleasant for the patient and expensive for healthcare providers.  
The identification and validation of bladder tumour-specific molecular markers in urine 
could enable tumour detection and reduce reliance on cystoscopy, and numerous classes of 
biomarkers have been studied. Proteins represent the most intensively studied class of 
biomolecule in this setting.   
As an aid to researchers searching for better urinary biomarkers, we report a 
comprehensive systematic review of the literature and a searchable database of proteins 
that have been investigated to date.  Our objective was to classify these proteins as: 1) 
those with robustly characterised sensitivity and specificity for bladder cancer detection; 2) 
those that show potential but further investigation is required; 3) those unlikely to warrant 
further investigation; and 4) those investigated as prognostic markers.   This work should 
help to prioritise certain biomarkers for rigorous validation, whilst preventing wasted effort 
on proteins that have shown no association whatsoever with the disease, or only modest 
biomarker performance despite large-scale efforts at validation.    
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INTRODUCTION 
Non-muscle-invasive bladder cancer (NMIBC: stages Ta/T1/Tis) is characterised by a high 
incidence of recurrence and a risk of progression to muscle-invasive disease (MIBC: stages 
T2+) [1].  Long-term surveillance thus remains the cornerstone of long-term management, 
and cystoscopy has represented the gold standard modality for over 80 years.  However, the 
cystoscopic approach is both burdensome for patients and expensive for healthcare 
providers, and so there has been a decades-long search for non-invasive urinary biomarkers 
that can match or even improve upon the sensitivity and specificity of cystoscopy.  However, 
current guidelines do not recommend the use of urinary biomarkers in the management of 
bladder cancer patients [2].  Despite this, urine cytology is often used as an adjunct to 
cystoscopy and whilst visual detection of cancer cells in urine is a very specific test with high 
sensitivity for high-grade bladder cancer, sensitivity for low-grade bladder cancer is only 4-
31% [3].  Thus any new biomarkers might be considered useful if they outperform cytology 
i.e show very high specificity and high sensitivity for both low and high-grade bladder 
cancer.    
Many classes of biomolecule have been investigated as urinary biomarkers but the majority 
of studies have analysed proteins with hundreds of published reports where specific 
proteins have been measured in urine as potential indicators of bladder cancer.  In this 
review we focus entirely on soluble proteins (those that can be measured in the 
supernatant rather than the pellet following centrifugation).  Most proteins can be 
measured reliably using inexpensive immunoassays.  These may be rapid and qualitative, 
enabling point-of-care testing, or laboratory based quantitative immunoassays but in either 
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case, multiplex testing for a panel of protein biomarkers (if such a panel was defined) should 
be relatively straightforward to implement.     
The proteins measured in biomarker studies will have been selected based on prior 
knowledge of the biology of bladder cancer or the biology of the particular protein or based 
on data from hypothesis generating approaches such as gene expression profiling and 
proteomic analyses of bladder cancer tissue, cell lines or indeed urine itself.  In most cases, 
the measurements will have been made using a validated antibody-based assay such as an 
ELISA.  The reliability of such assays is dependent on the specificity of the antibodies used; 
certain types of assay which rely on the specificity of a single antibody may be more 
susceptible to interference than ‘sandwich assays’ (those that rely on the specificity of a pair 
of antibodies).  However, in many bladder cancer biomarker studies, patient selection is of 
more concern than the assay used.  That is to say, “do the patients (and the non-cancer 
subjects) being used in the study represent the patient population where the biomarker test 
would be applied in the real world?”.  Ideally in studies of biomarkers for first presentation 
diagnosis both “cases” and “controls” should be patients undergoing investigation for 
suspected bladder cancer e.g. patients from haematuria clinics.  For surveillance markers 
both cases and controls should be patients undergoing surveillance for disease recurrence.  
However, in many biomarker studies we see bias introduced by  enrichment for high-grade 
and advanced disease which is likely to increase apparent sensitivity (% cases correctly 
identified) and inclusion of healthy volunteers which is likely to increase apparent specificity 
(% controls correctly identified), or the use of patients with large-primary tumours when the 
goal is to detect small recurrent tumours [4]. 
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Another major pitfall in the measurement of urinary biomarkers for bladder cancer is 
haematuria [5]:  haematuria is a symptom and sign of bladder cancer but is not the 
biological cause of bladder cancer.  Thus, any protein present in blood may appear to act as 
a biomarker in case-control studies where haematuria is not matched, but will not be 
bladder cancer-specific. 
Reviews of urinary biomarkers for bladder cancer (e.g. [6, 7]) tend to focus on the 
biomarkers that have been most extensively validated for detecting disease, especially 
those with FDA approval (NMP22, BTA, UroVysion, ImmuoCyt), but also others such as 
MMP9 which have been extensively measured but fall short of clinical utility, and perhaps a 
handful of ‘promising candidates’.  In the current review we attempt to comprehensively 
review all proteins which have been investigated as urinary biomarkers for bladder cancer.  
Our main rationale for doing so is to generate a useful resource for researchers that may 
indicate the potential (or otherwise) of a particular urinary protein under investigation.  A 
secondary aim of is to collate and assess the literature on prognostic urinary biomarkers, an 
area which is often neglected but which could be incorporated into risk stratification 
algorithms and so aid patient management. 
The biomarker studies reviewed are heterogeneous in terms of the populations studied.  
The non-bladder cancer control cohorts vary from healthy controls to non-malignant 
urological disorders to non-bladder urological malignancies and patients undergoing 
surveillance for bladder cancer recurrence with no detectable disease (or a mix of all four).  
The bladder cancer cases vary in stage and grade (which we have partially controlled for 
with our selection criteria, see below) but are also either primary or recurrent tumours or a 
mix of both (or unspecified) in different studies.  Thus, to be inclusive, we have used the 
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term “detection biomarker” and present sensitivity for bladder cancer versus non-bladder 
cancer throughout this review rather than attempting to distinguish between proposed 
diagnostic and surveillance roles for biomarkers in individual studies.       
 
MATERIALS AND METHODS 
Systematic review methods were employed to find primary studies that reported test 
results on measured soluble protein biomarkers in urine. The search was conducted in 
Medline via the Pubmed search platform on the 25th August 2015 using the following search 
terms: (("urinary bladder neoplasms"[MeSH Terms] OR ("urinary"[All Fields] AND 
"bladder"[All Fields] AND "neoplasms"[All Fields]) OR "urinary bladder neoplasms"[All Fields] 
OR ("bladder"[All Fields] AND "cancer"[All Fields]) OR "bladder cancer"[All Fields]) AND 
("urine"[Subheading] OR "urine"[All Fields] OR "urine"[MeSH Terms])) AND ("biological 
markers"[MeSH Terms] OR ("biological"[All Fields] AND "markers"[All Fields]) OR "biological 
markers"[All Fields] OR "biomarker"[All Fields]).  Studies retrieved from the PubMed search 
were assessed for eligibility by two people (JD & JG) using the title and abstract or where 
necessary the full text. Disagreements regarding inclusion were resolved by discussion and 
moderation by the rest of the team.    Papers were included if they reported on tests that 
measured soluble protein biomarkers in the urine of bladder cancer patients (any stage).  
We excluded papers that did not measure protein biomarkers in urine, measured only 
enzyme activities, or that analysed urinary cell pellets.  Prognostic biomarker studies were 
manually identified from the full set of included publications.    
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The included papers underwent a quality filter step to separate the better designed and 
reported studies from those with poor reporting or design.  Studies were categorized into 
“unequivocal” or “equivocal” categories based on whether they met the following selection 
criteria: 
• ≥ 20 cancer patients  
• ≥ 20 controls or more 
• Specificity and sensitivity presented 
• ≥25% pTa bladder cancer  
• ≥ 15% grade 1 bladder cancer 
The thresholds for the percentage of pTa and grade 1 tumours are well below the 
percentages for incident bladder cancer in the UK [8] but enable identification of studies 
with bias towards reporting protein biomarkers associated with high-grade/stage bladder 
cancer.  Studies which were not available to view or purchase online were also excluded.  
The proteins reported in unequivocal studies were further categorised into those in 3 or 
more unequivocal studies (validated detection biomarkers), those with a combined 
sensitivity and specificity (sensitivity+specificity/2) ≥ 80% (possible biomarkers), and those 
with a combined sensitivity and specificity ≤ 80% (unlikely biomarkers).  The value of 80% 
for combined specificity and sensitivity was selected on the basis that it is close to the 
performance of cystoscopy, the gold standard to which biomarkers are usually referenced 
(which is the only method of detection of bladder cancer recommended by NICE [2]).  The 
reported sensitivity and specificity of white light cystoscopy vary greatly but a recent meta-
analysis arrived at values of 85 and 87% [9].  The full search and categorisation strategy is 
shown in Figure 1. 
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RESULTS 
Search Result Overview  
Our initial literature search identified 1310 publications.  From these, we identified 350 
reports in which one or more proteins were measured in the urine of bladder cancer 
patients.  Of the 350 reports, only 49 meet our criteria to be considered as “unequivocal”.  
The remaining 301 studies either have too few cases or controls, do not report a high 
enough proportion of pTa and/or grade 1 tumours, do not provide values for sensitivity and 
specificity, or are not readily accessible.  In total, we found evidence that 161 proteins have 
been investigated as urinary biomarkers for bladder cancer (Table 1 and Supplemental 
Information Table S1).  
Validated detection biomarkers 
Of the 161 proteins investigated, 27 were investigated in one or more “unequivocal studies” 
(Table 1).  Only 4 proteins appear in 3 or more of the unequivocal studies and thus meet our 
criteria as “validated detection biomarkers”.  These are the well-known biomarkers: nuclear 
matrix protein 22 (NMP22), bladder tumour antigen (BTA), and the cytokeratin-based tests 
urinary bladder carcinoma antigen (UBC) and Cyfra 21-1.  NMP22, BTA and UBC are 
commercially available as both quantitative and point-of-care assays.  NMP22 (gene symbol: 
NUMA1)  is a nuclear matrix protein overexpressed in bladder cancer cells and has been 
measured in 25 unequivocal studies with weighted mean sensitivity and specificity of 61.8% 
and 80.3%, respectively (4528 cancer patients vs. 7728 non-cancer).  The antigen recognised 
in the BTA assay is reported as complement factor H related protein which is released from 
bladder cancer cells [10]: the weighted mean sensitivity and specificity for using BTA to 
detect bladder cancer across 23 unequivocal studies are 64.0% and 76.6%, respectively 
(2258 cancer patients v 2994 non-cancer).  The UBC test measures soluble fragments of 
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cytokeratins 8 and 18 and has been reported in 11 unequivocal studies with a mean 
sensitivity and specificity of 64.4% and 80.3%, respectively (753 cancer patients v 1072 non-
cancer).  The Cyfra 21-1 test measures soluble fragments of cytokeratin 19 and has been 
reported in 3 unequivocal studies with a mean sensitivity and specificity of 64.4% and 
85.5%, respectively (293 cancer patients v 331 non-cancer). 
The mean sensitivities and specificities for the 4 well validated biomarkers across multiple 
studies are all very similar, in accordance with studies performing side-by-side comparisons: 
the results of such studies vary as to which biomarker performs best but seldom find 
substantial differences between them [11-13].  All 4 validated biomarkers also show a 
similar dependence on stage and grade with high sensitivity for high-grade and muscle-
invasive disease but lower sensitivity for low-grade disease.  Based on data from those 
studies listed in Table 1 which present sensitivity for different grades of disease, the mean 
sensitivities for grade 1/grade 3 are 53.4%/77.4% for NMP22, 51.4%/87.5% for BTA, 
48.5%/76.0% for UBC and 55.7%/91.9% for Cyfra 21-1.  Thus, these markers do have higher 
sensitivity for low-grade disease than cytology (albeit with lower specificity) but fall short of 
cystoscopy in terms of both sensitivity and specificity [3, 9].  Whilst there may be some 
utility for these commercially-available biomarkers in the surveillance of HR-NMIBC (when 
index tumour grade and stage are known), they cannot be solely relied upon for the 
diagnosis of incident disease.  
     
Possible biomarkers  
There are 11 proteins that have been evaluated in an unequivocal study and have a 
combined sensitivity and specificity (sensitivity+specificity)/2) of greater than 80%.  We have 
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designated these as “possible biomarkers”.  They are apolipoprotein A4, calprotectin, 
CD147, CEACAM1, clusterin, coronin-1A, DJ-1, fibronectin, reg-1, stathmin-1, and ϒ-
synuclein.  Several of these possible biomarkers are also supported by evidence from 
“equivocal studies”.  Each protein is discussed briefly below.  These are proteins that may 
merit further investigation: all require independent validation in appropriate patient 
cohorts. 
The utility of urinary fibronectin for detecting bladder cancer reported in 2 unequivocal 
studies [14, 15] is supported by 9 “equivocal” studies: 5 of these studies present moderately 
high sensitivities and specificities with weighted means across the studies of 82.5% and 
80.2%, respectively (390 cases and 520 controls) [16-20].  Although there is substantial 
evidence that increased urinary fibronectin is indicative of bladder cancer, Alias-Melgar [21] 
found that urinary fibronectin is increased in urolithiasis, and EIssa [17] reported that in 
side-by–side comparison NMP22 slightly outperforms fibronectin.     
The utility of urinary clusterin is also reported by 2 unequivocal studies [22, 23] and 1 
equivocal study [24] with the latter reporting a sensitivity of 73% but only 55% specificity.  
Clusterin is a multifunctional chaperone protein with alternatively spliced forms exhibiting 
different cellular locations and functions [25].  Hazzaa et al [22] found increased clusterin 
gene expression in bladder cancer, particularly in invasive disease, and that high clusterin 
expression was associated with  poor prognosis.  Although clusterin is widely expressed and 
found in all body fluids, which may limit it’s specificity [26], measurement of individual 
splice variants rather than total clusterin levels might merit further research.    
CEACAM1 (Carcinoembryonic antigen-related cell adhesion molecule 1, also known 
as CD66a) was reported as a novel urinary marker for bladder cancer by Tilki et al [27].  In 
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this study comparing 93 cases (72 NMIBC, 17 low-grade) with 82 controls (30 healthy 
subjects, 10 with benign disease and 42 with a history of bladder cancer but no evidence of 
disease) urinary CEACAM1 generated a sensitivity of 74% at 95% specificity.  As with most 
urinary biomarkers sensitivity was higher for MIBC than NMIBC.  It is not stated whether the 
tumours were incident or recurrent and subjects with diabetes were excluded from the 
study but CEACAM1 appears to merit further investigation.  Tilki et al [27] also reported that 
CEACAM1 immunostaining was detected on endothelial cells rather than cancer cells in 
bladder tumours.  It has not been reported whether the urinary CEACAM1 is expressed as a 
soluble isoform (lacking the transmembrane domain) or if the ectodomain is shed by 
proteolytic cleavage. 
Ebbing et al [28] reported that urinary calprotectin (a heterodimer of S100A8 and S100A9 
proteins with antimicrobial properties) can be used to detect bladder cancer with 80% 
sensitivity at 92% specificity in a study with 46 cases (38 NMIBC, 25 low-grade) and 40 
healthy controls.  The median calprotectin level was 10-fold higher in bladder cancer 
patients than healthy controls and less than 2-fold increased in patients with prostate and 
renal cancers (although their inclusion in the data analysis slightly decreased specificity).  
Calprotectin has been reported as a prognostic indicator in bladder cancer and to be 
upregulated both in tumours and sera [29, 30].  However, calprotectin is released by 
neutrophils during inflammation which may compromise its role as a tumour marker.  
Two urinary proteins, stathmin-1 and CD147 make the “possible biomarkers” category on 
the basis of a study by Bhagirath et al [31] analysing the urine of 30 bladder cancer cases (21 
NMIBC, 13 low-grade) and 30 controls (15 healthy, 15 benign prostatic hyperplasia).  
Sensitivities and specificities were 90% and 87% for stathmin-1, respectively (also known as 
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oncoprotein-18) and 97% and 100% for CD147, respectively (also known as basigin or 
EMMPRIN).  Although a small single study, both stathmin-1 and CD147 are known cancer-
related proteins and there are reports that overexpression of stathmin-1 [32] and CD147 
[33] are associated with aggressive bladder cancer and a poor prognosis.    
Another 4 possible biomarkers were reported in a study by Kumar et al [34]:  ϒ-synuclein 
(87.5% sensitivity at 90.0% specifity), DJ-1 (83.3% sensitivity at 100% specificity), 
apolipoprotein A4 (79.2% sensitivity at 100% specificity) and Coronin-1A (66.7% sensitivity 
at 100% specificity) based on 173 cases (110 NMIBC, 89 low-grade) and 212 controls (66 
healthy, 91 other malignancy, 121 assorted chronic conditions).  Various apolipoproteins 
have been reported as increased in the urine of bladder cancer patients [35-37]; however, 
being moderately abundant in plasma, their specificity is not assured and, in the case of 
apolipoprotein A4, Chen et al [38] found no evidence of elevation in bladder cancer 
patients.  ϒ-synuclein was also investigated by one equivocal study which reported only 
40.2% sensitivity albeit at 96.5% specificity [39] (112 cancer and 230 controls).  Although DJ-
1 has been reported to be overexpressed in aggressive high-grade bladder cancer [40], no 
other urine studies have been published.  We have performed a pilot study and found 
urinary DJ-1 to be significantly increased only in MIBC, disputing a high sensitivity for all 
stages and grades of bladder cancer (Ward, unpublished data).  Coronin-1A is a cytoskeletal 
protein that has not been otherwise reported in bladder cancer.  It seems likely that Kumar 
et al’s study [34] may have overestimated the performance of these 4 possible biomarkers. 
Using proteomics, Orenes-Piñero et al [41] identified a protein at increased levels in the urine of 
bladder cancer patients as Reg-1 (lithostathine-1-alpha).  Immunohistochemistry showed Reg-
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1 overexpression in bladder tumours and measurement in 32 cases (16 NMIBC, 5 low-grade) 
and 48 controls (cystoscopy negative) gave 81% sensitivity at 81% specificity. 
 
Unlikely biomarkers 
Sixteen of the 27 proteins evaluated in unequivocal studies have a combined sensitivity and 
specificity of less than 80% (including the 4 validated detection biomarkers).  As the 
diagnostic performance of these proteins is well below that achieved by flexible cystoscopy 
it is unlikely that any of these would find widespread clinical use as standalone biomarkers 
for detecting bladder cancer.  Nonetheless, the evidence suggests that some cases of 
bladder cancer result in an increase in the urinary concentration of these proteins and 
consequently they may be diagnostically useful when used in combination with one another 
or other markers. 
Equivocal biomarkers 
We found that the majority of the biomarker studies we reviewed could not be classified as 
unequivocal.  This is due to missing information (stage/grade/sensitivity/specificity) or due 
to a non-representative patient population which is likely to inflate the estimated sensitivity 
and specificity.  Fifteen proteins that have not been investigated in an unequivocal study 
have been evaluated in at least 5 equivocal studies (Figure 2), and some of the equivocal 
studies report high sensitivities and specificities.  With the caveat that these “equivocal 
biomarkers” may not be robust in the clinical setting, we briefly discuss those reported in 5 
or more studies below. 
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Urinary carcinoembryonic antigen (CEA) has been investigated in 28 equivocal studies. The 
weighted mean values for sensitivity and specificity are 54.0% and 90.5% respectively (814 
cases and 578 controls) based on accessible studies reporting sensitivity and specificity [42-
47]. Most of the CEA studies were published in the 1970s and 1980s (Figure 3) and interest 
presumably waned due to the sensitivity being too low for clinical utility.  However, as 
expected for an oncofetal antigen, specificity appears to be high and therefore urinary CEA 
could prove useful in the context of a multimarker panel.          
The role of matrix metallopeptidase 9 (MMP9) as a urinary biomarker has been investigated 
in 16 equivocal studies with 8 presenting values for sensitivity and specificity [48-55].  The 
weighted mean values for sensitivity and specificity are 72.1% and 77.2%, respectively 
(based on 707 cases and 917 controls).   MMP9 is biologically plausible as a biomarker for 
invasive bladder cancer and urinary levels are clearly elevated in many cases of bladder 
cancer; however, modest sensitivity and specificity (especially for low-grade disease) limit its 
usefulness.  
Urinary vascular endothelial growth factor (VEGF) has been investigated in 13 equivocal 
studies with 6 presenting sensitivity and specificity data [48, 54, 56-59].  The weighted mean 
values for sensitivity and specificity are 71.4% and 78.1%, respectively (based on 509 cases 
and 389 controls).  
Tissue polypeptide antigen (TPA, a complex of cytokeratins 8, 18 & 19) has been 
investigated in 10 equivocal studies with 3 presenting sensitivity and specificity data [46, 60, 
61]. The weighted mean values for sensitivity and specificity are 84.1% and 96.6%, 
respectively (based on 277 cases and 311 controls).  However, Stefanovic et al reported that 
TPA lacks diagnostic accuracy [62], and Carbin et al reported that TPA is only effective if 24 
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hour urine samples are analysed [63].  Additionally, although the averaged 
sensitivity/specificity appear higher than the averaged sensitivity/specificity for other 
cytokeratin based tests (UBC and Cyfra 21-1), in a direct comparison of TPA and Cyfra 21-1 
Sanchez-Carbayo found TPA to be slightly inferior to Cyfra 21-1, indicating that the equivocal 
studies have overestimated the performance of TPA [61, 62].    
Survivin has been investigated in 9 equivocal studies with 6 reporting sensitivity and 
specificity data [58, 64-68].  The weighted mean values for sensitivity and specificity are 
69.4% and 88.3%, respectively (based on 437 cases and 313 controls).  
Matrix metallopeptidase 2 (MMP2) has been investigated in 8 equivocal studies with 4 
presenting sensitivity and specificity data [49, 52, 53, 69]. The weighted mean values for 
sensitivity and specificity are 68.2% and 88.8%, respectively (based on 345 cases and 681 
controls).   
A number of interleukins have been repeatedly investigated in the urine of bladder cancer 
patients.  Interleukin-8 (IL-8) has been investigated in 10 equivocal studies with 4 presenting 
sensitivity and specificity data [54, 56, 70, 71]. The weighted mean values for sensitivity and 
specificity are 66.4% and 83.1%, respectively (based on 225 cases and 273 controls).  
Interleukins 2 and 6 (IL-2 and IL-6) have been measured in 5 and 7 equivocal studies 
respectively.  However most of these studies focus on response to BCG treatment rather 
than bladder cancer detection [72].  With only one study [56] reporting sensitivity and 
specificity data for IL-6 (67% and 63%), and none for IL-2, there is no evidence that either is 
likely to be useful for detecting bladder cancer.  
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CA19-9 has been investigated as a urinary biomarker in 8 equivocal studies, but with only 
two reporting sensitivity and specificity (83.3% and 50.8% [73], and 71.6% and 91.6% [74], 
respectively).  Strictly speaking, this is a glycan biomarker rather than a glycoprotein 
biomarker [75].  CA19-9 may be a useful biomarker for bladder cancer when interpreted 
with reference to secretor phenotype [76, 77].  
BCLA-4 has been investigated as a urinary biomarker in 6 equivocal studies. BCLA-4 was first 
reported in 1996 as a spot in 2D-electrophoresis analyses of nuclear matrix extracts that was 
more intense in bladder cancer than normal urothelium [78].  The authors then partially 
sequenced the protein in the gel spot and generated antibodies to a synthetic peptide 
(EISQLNAG), despite the sequence not matching any known human protein sequences.  The 
antibodies were used to generate immunoassays and BCLA-4 measured in the urine of 54 
bladder cancer patients (predominantly high-grade) and 51 control subjects, generating a 
sensitivity of 96.4% at 100% specificity [79].  In 2004 the same group identified BCLA-4 as a 
member of the ETS transcription family [80] and then expanded their study to 70 cancer 
subjects and 147 controls (89% sensitivity and 95% specificity) [81].  However, both of these 
papers have now been retracted [82, 83].  Despite this, BCLA-4 has been widely reported as 
a ‘promising biomarker’ in previous reviews and a further study in China using antibodies 
raised against the EISQLNAG sequence have reported very high sensitivity and specificity 
[84].  Thus, BCLA-4 has a chequered history and although BCLA-4 ELISAs appear to detect 
bladder cancer better than other urinary markers, BCLA-4 has neither gained regulatory 
approval or been widely adopted as a urinary biomarker for bladder cancer detection.   
Apolipoproteins A1 (APOA1) and E (APOE) and have been investigated in 5 and 6 equivocal 
studies respectively.  The 5 APOA1 papers are from 2 research groups with both reporting 
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high sensitivity and specificity (89.2% and 84.6% [85-87], and 94.6% and 92.0% [38, 88], 
respectively).  Apolipoproteins are abundant in plasma and hence urinary concentrations 
will be influenced by haematuria.  The study by Chen et al [88] included 13 control subjects 
with haematuria and their urinary APOA1 was slightly elevated; the authors concluded that 
urinary APOA1 might need to be interpreted with reference to haematuria.  As a urinary 
biomarker, APOE appears less useful than APOA1 [36-38, 48].   
We were unable to find any consistent evidence of high sensitivity or specificity for any of 
the remaining proteins mentioned in 5 unequivocal studies (ICAM-1, β-gonadotropin, E-
cadherin, carbonic anyhdrase IX), although we note that carbonic anhydrase IX urinary 
mRNA has recently been reported as a potentially useful biomarker [89]. 
In summary, none of the biomarkers investigated in ≥ 5 equivocal studies has the sensitivity 
and specificity required to act as a standalone biomarker for detecting bladder cancer.  
Finally, in our search for unproven but possible biomarkers we manually searched the 
reports for the proteins presented in <5 equivocal studies for those the highest sensitivity 
and specificity.  MMP3 and TIMP2 showed high sensitivity and specificity in studies carried 
out in Egypt [49, 51].  These results should be treated with caution as in Egypt many cases of 
bladder cancer are bilharzial SCC.  Additionally, TIMP2 has been reported to have lower 
sensitivity and specificity in other studies.  A small study by Gecks et al [90] suggested that 
Tenascin-C can be used to detect recurrent bladder cancer with 91% sensitivity at 80% 
specificity.  In a study using urine from 68 cases (mixed stage and grade), 68 healthy controls 
and 16 patients with cystitis Lorenzi et al [91] reported that measuring the serine peptidase 
HTRA-1 gave 92.7% sensitivity and 95.6% specificity for bladder cancer detection.  At the 
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time of writing no further studies have corroborated (or refuted) the biomarker potential of 
HTRA1-1.      
   
Prognostic urinary biomarkers 
Urinary biomarkers have the potential to inform not only on the presence or absence of 
bladder cancer, but also to provide prognostic information.  Such a biomarker would 
provide information on outcome and could guide choices between conservative and radical 
treatment regimens.  The word ‘prognostic’ has been applied variably to urinary biomarkers.  
For example, high levels of biomarker post resection are often reported as a poor prognostic 
indicator, but are most likely just indicative of residual disease.  A truly prognostic indicator 
should indicate outcome in patients with tumours; not versus those without tumours.  The 
majority of urinary protein biomarkers considered in this review increase in concentration 
with both stage and grade of disease and could therefore be considered as prognostic 
indicators.  However, very few studies have directly investigated the association between 
urinary biomarker levels at presentation and outcome, and even fewer have investigated 
whether urinary biomarkers can provide prognostic information over and above that 
provided by standard clinicopathological factors (Table 2).  Indeed, at the time of writing, 
only BTA, CEA, MMP9, tenascin-C, cystatin-B and the soluble extracellular domains of EGFR 
and EpCAM have been reported as independent prognostic indicators (Table 2) and these 
data require independent validation.   The two NMP22 prognostic studies listed in Table 2 
confuse disease detection and prognosis, although further literature searching identified a 
large study by Shariat et al [92] which found that including pre-treatment urinary NMP22 
levels slightly improved the ability of nomograms to predict later recurrence.    
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 Biology of urinary biomarkers 
The proteins that have been shown to be increased in concentration in the urine of bladder 
cancer patients are highly diverse in terms of their biological activities, the pathways that 
they are involved with and their cellular compartmentalisation. They include, amongst 
others, proteases, lipid binding/transport proteins, cytoskeletal components and cytokines.  
The most significantly over represented biological processes include “regulation of cell 
migration”, “response to wounding”, “regulation of apoptosis” and “inflammatory 
response” [93].  Eight of the proteins are in the KEGG_PATHWAY “Pathways in Cancer” 
(survivin, E-cadherin, fibronectin, IL6, MMP2, MMP9, PDGFR and VEGF).  Other proteins are 
less obviously mechanistically linked to cancer with Apo-A1, apo-A4, apoE, clusterin, 
fibrinogen, fibronectin, thrombin and α1-antitrypsin all classed as plasma proteins and with 
α1-antitrypsin, thrombin, IL6 and fibronectin also being classed as acute phase proteins.  
Over half of the proteins are bona fide secreted proteins, but there are also 7 
cytoplasmic/cytoskeletal and 6 plasma membrane proteins and 2 nuclear proteins (NMP22 
and EN2) (Figure 4).   
 
DISCUSSION 
We have systematically reviewed the literature concerning urinary proteins as biomarkers 
for bladder cancer.  We focussed solely on proteins which are measured in solution in urine, 
rather than proteins present in cancer cells in the cell pellet or DNA, RNA or metabolite 
biomarkers.  Thus, all of the biomarkers discussed above can be measured by immunoassay 
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in a single urine sample which may enable biomarker multiplexing and point-of-care testing 
in the future.  
We found that the majority of urine biomarker studies use patient populations enriched for 
high-grade and high-stage disease which is likely to inflate estimates of sensitivity and 
specificity and/or do not provide sufficient information to be thoroughly evaluated.  It is 
clear that the urinary concentrations of the vast majority of proteins investigated as 
biomarkers positively correlate with both stage and grade of disease.  Thus, low stage and 
grade disease is not easily detected.  As low and high-grade bladder cancer can be 
considered separate entities at the genomic level [94], it might be expected that different 
urinary biomarkers would be required to detect each.  By definition, the cancer cells are still 
relatively normal, both genomically and phenotypically, in low-grade disease so that  
although some alterations in gene expression have been noted [95], the processes involved 
in releasing proteins into the urine may be essentially normal.  With high-grade and invasive 
disease it is likely that many of these processes are unregulated such that proteins released 
directly from the cancer cells, as breakdown products from the extracellular matrix, as a 
result of inflammatory responses or plasma proteins all find their way into the urine.  Thus, 
although high-grade bladder cancer is a heterogeneous disease, it is perhaps not surprising 
that many of the urinary proteins reviewed can detect high-grade and stage disease with 
high sensitivity.  A panel of protein markers, carefully selected on the basis of close 
associations with the various molecular sub-types of bladder cancer might offer the way 
forward in facile non-invasive detection of bladder cancer. 
Our review shows that the use of pre-treatment urinary biomarker levels for 
prognostication has been addressed in very few studies compared with disease detection.  
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This may be due to the long-term follow up of patients required for such studies, the lack of 
a perceived need for such biomarkers or the fact that in patients with a confirmed tumour 
molecular markers can be measured directly in the tumour rather than in urine.  It is 
however possible that processes which release proteins from tumours (secretion, leakage, 
shedding) and degradation of the surrounding urothelium are important prognostic 
indicators and are more effectively measured in urine than in the tumour itself.    
 In accord with others, we find that the “validated detection markers” (NMP22, BTA, UBC, 
Cyfra 21-1) do not rival flexible cystoscopy in terms of sensitivity and specificity [96].  We 
also find that many other biomarkers with are often reported as “promising” are not 
genuinely promising as their sensitivity or specificity is too low, or the evidence supporting 
their utility is equivocal.  Finally, we have highlighted a small number of proteins that might 
warrant further validation and hopefully be confirmed as clinically useful biomarkers.     
There are several limitations related to the review methodology. Firstly we may have 
introduced publication bias as we couldn’t access all of the publications online, however, as 
most were published before the year 2000 we reasoned that if that particular biomarker 
was significant, then the publication trail would have continued beyond 2000. Secondly, the 
review may be skewed to more positive data due to publication bias present in the 
literature i.e. only positive results get published. Thirdly, as we only included studies which 
reported both sensitivity and specificity, we could have been affected by outcome reporting 
bias i.e. where studies report selected outcomes usually those that are positive [97]. Despite 
these limitations we believe this review presents a comprehensive summary of the 
literature and a searchable database of proteins that have been investigated to date (Table 
S1), which will aid researchers searching for better urinary biomarkers.  We conclude that: 
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• The majority of urine biomarker studies contain bias or are insufficiently reported. 
• The urinary concentrations of a large number of proteins are increased by the 
presence of bladder cancer, but most proteins are not increased in all cases and are 
not specific to bladder cancer. 
• NMP22, BTA, UBC and Cyfra 21-1 are the only well-validated urinary protein 
biomarkers and their sensitivity and specificity are well below those of cystoscopy. 
• Fibronectin, clusterin, CEACAM1, apolipoprotein A4, calprotectin, CD147, coronin-
1A, DJ-1, reg-1, stathmin-1, and ϒ-synuclein may be considered as possible 
biomarkers.   
• Biomarkers supported by multiple “equivocal” studies include CEA, MMP9, VEGF, 
TPA, survivin, CA19-9, APOA1 and BCLA-4.  Of these, only BLCA-4 reportedly has 
high-sensitivity, but is mired in controversy. 
• Biomarkers supported by a single “equivocal” report of high sensitivity and 
specificity include MMP3 and HTRA. 
None of the urinary protein biomarkers investigated to date can be used for accurate non-
invasive detection of bladder cancer.  Current efforts to combine protein biomarkers to 
improve test accuracy also fail to reach clinically useful sensitivity and specificity [48, 98].  
DNA/RNA-based markers may supersede protein biomarkers in the near future [99-103]; 
however, with currently-available technology, these are more complex, expensive and time-
consuming to measure than protein markers with little potential for point-of-care testing in 
the immediate future. Notwithstanding, we hope that the increasing understanding of 
bladder cancer at the molecular-genomic level may enable selection of the correct cancer-
specific proteins (or variants of proteins) to underlie a clinically applicable biomarker panel.  
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Table1. 
 
 
Protein 
name Gene  symbol 
Sensitivity  
(%) 
Specificity  
(%) 
Cancers  
(n) 
Controls  
(n) Refs 
Alpha-1-anti-
trypsin SERPINA1 70.6 71.8 206 102 [104] 
Angiogenin ANG 66 75 50 20 [23] 
Apolipoprote
in A4 APOA4 79.2 100 110 66 [34] 
Autocrine 
motility 
factor 
receptor 
AMFR 84 75 45 62 [105] 
BIGH3 TGFBI 70 80 30 30 [31] 
Bladder 
tumour 
antigen (BTA) 
BTA# 64 76.6 2258 2994 [11, 12, 55, 106-125]  
Calprotectin S100A8 & S100A9 80.4 92.5 46 135 [28] 
Cathepsin B CTSB 55.7 56.1 122 107 [126] 
Cathepsin L CTSL 71.3 74.8 122 107 [126] 
CCL18 CCL18 70.4 67.7 206 102 [104] 
CD147 
(EMMPRIN) BSG 96.7 100 30 30 [31] 
CEACAM1 CEACAM1 74 95 93 82 [27] 
Clusterin, CLU 76.3 86.5 168 151 [22, 23] 
Coronin-1A CORO1A 66.7 100 110 66 [34] 
CYFRA21-1 KRT19 64.4 85.5 293 331 [127-129] 
DJ-1 PARK7 83.3 100 110 66 [34] 
EN2 EN2 82 75 466 52 [130] 
FDP FGA & FGB 52 91 57 139 [107] 
Fibronectin FN1 89 85.6 126 41 [14, 15] 
NMP22 NUMA1 61.8 80.3 4528 7728 
[11, 12, 107-112, 116-118, 120, 123, 126, 
131-141] 
 
PDGFRβ PDGFRB 70.6 81.2 117 68 [142] 
Prothrombin F2 71.1 75.0 76 80 [143] 
Reg-1 REG1A 81.3 81.2 32 48 [41] 
Semenogelin
-2 SEMG2 66.7 80 110 66 [34] 
Stathmin-1 STMN1 90.0 86.7 30 30 [31] 
Urinary 
bladder 
carcinoma 
antigen 
(UBC) 
KRT8 & 
KRT18 64.4 80.3 753 1072 [11, 12, 106, 112, 113, 131, 144-148] 
γ-synuclein, SNCG 87.5 90.0 110 66 [34] 
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 Table 2. 
Marker 
No. of 
studies 
No. of 
patients Comments Refs 
BTA 1 97 Independent prognostic indicator  [149] 
Carcinoembryonic antigen (CEA) 3 425 Independent prognostic indicator [44, 47, 150] 
β-HCG 1 52 Prognostic in MIBC [151] 
EGFR 1 436 Independent prognostic indicator [152] 
EpCAM 1 607 Independent prognostic indicator [152] 
MMP9 1 188 Independent prognostic indicator [153] 
NMP22 2 333 Detection-prognosis [109, 154] 
Plasminogen  Activator Inhibitor type I (PAI-1) 1  244 Not prognostic [155] 
PDGFRβ 1 185 Predicts recurrence in NMIBC [142] 
Tenascin-C 1 66 Independent prognostic indicator [156] 
Tissue polypeptide antigen (TPA) 1 97 Prognostic [157] 
Urinary sFas 1 128 Predicts recurrence in NMIBC [158] 
Urine tumour-associated trypsin inhibitor(TATI) 1 157 Not prognostic [159] 
Cystatin-B 1 47 Independent prognostic indicator [160] 
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LEGENDS. 
Table 1.  Summary of unequivocal biomarker studies.  For proteins with multiple studies, 
sensitivity and specificity are presented as means weighted according to sample size in each 
study. #indicates potentially several genes.  NMP22, BTA and UBC data include studies using 
quantitative and point-of-care versions of the assay.  
Table 2.  Prognostic urinary biomarkers for bladder cancer. 
Figure 1.  Search strategy outline and results. 
Figure 2.   Numbers of publications for the most commonly investigated urinary protein 
biomarkers.  Papers providing measurement data included, reviews excluded.     
Figure 3.  The history and lifecycle of bladder cancer biomarkers.  The number of 
publications for each biomarker with >10 publications in total is shown for each half-decade 
from 1971.  CEA peaks in the 1970s and TPA in the 1980s.  BTA and cyfra 21-1 peak in 1996-
2000 whilst fibronectin, NMP22 and UBC peak in 2001-2005.  The rate of publication of all of 
these biomarkers are now declining whereas MMP9 and VEGF continue to rise.  
Figure 4.   Cellular compartmentalisation of protein biomarkers reported ≥ 1 unequivocal or 
≥5 unequivocal biomarker studies. 
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Figure 1. 
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Figure 2. 
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Supplemental Information Table S1.  List of unequivocal biomarker studies. 
Gene names are provided where available.  Assays for which the biomarker cannot be 
unambiguously identified as the product of a single particular gene are indicated with an 
asterisk.   
Proteins Gene symbols Reference 
 alpha-1-antitrypsin SERPINA1 Yang, Feng et al. 2011 
IL8, MMP9, MMP10, 
SERPINA1, VEGFA, ANG, 
CA9, APOE, SDC1, and 
SERPINE1 
IL8 MMP9 MMP10 SERPINA1 VEGFA ANG CA9 APOE SDC1 SERPINE1 Chen, Chang et al 2014 
Acidic Fibroblast growth 
factor 
FGFA Chopin, Caruelle et al. 1993 
ADAM28, SPINK5, PTP1 ADAM28  SPINK5 PTP1 Tyan, Yang et al. 2011 
Afamin, Alpha-1-anti-
trypsin, Alpha-2-HS-
glycoprotein,Angiotensin
ogen, Apolipoprotein A-II 
precursor, 
Apolipoprotein L1, 
Complement C9, nter-
alpha-trypsin inhibitor 
HC, Plasminogen, 
Thrombospondin-1 , 
Transferrin  
AFM SERPINA1 AHSG AGT APOA2 APOL1 C9 ITIH-X PLG THBS1 TF Chen, Chen et al 2012 
alpha-1-antitrypsin 
Apoloprotein E 
SERPINA1 APOE Urquidi V, Goodison S, et al 
2012 
Angiogenin ANG  Eissa, Kenawy et al. 2004  
Angiogenin, VEGF, 
Carbonic anyhdrase IX, 
BTA 
ANG VEGF* CA9 Complement_factor_H_related_protein* Urquidi V, Goodison S, et al 2012 
Apo-A1 APOA1 Li, Li et al 2011 
Apo-A1 APOA1 Li, Li et al 2013 
Apo-A1 APOA1 Li, Li et al. 2014 
APOA1 APOA4 Heparin 
cofactor II Peroxiredoxin-
2 
APOA1 APOA4 SERPIND1 PRDX2 
Chen, Chen et al 2010 
APOA1, APOA2, APOB, 
APOC3, APOC2, APOE, 
APOA4, TIM, SAA4, 
ProEGF 
APOA1 APOA2 APOB APOC3 APOC2 APOE APOA4 SAA4 TIM EGF Chen, Lin et al. 2013 
APOA2 APOA2 Chen, Chen et al. 2015 
Autocrine motility factor 
(AMF) 
Autocrine_motility_factor* Guirguis, Schiffmann et al. 
1988 
Basic fetoprotein Basic_fetoprotein* Ichikawa, Nakayama et al. 
2000 
Basic Fetoprotein Basic_fetoprotein* Tsujii, Yonese et al. 1990 
BLCA-4 
BLCA-4_(unknown) Van Le, Miller et al. 2005 
RETRACTED 
beta human chorionic 
gonadotrophin gonadotropin* 
McLoughlin, Pepera et al. 
1993 
Beta-2 Microglobulin B2M Engström 1988 
Bikunin AMBP Tsui, Tang et al. 2010 
BLCA-4 BLCA-4* Feng, Wang et al. 2011 
BLCA-4 BLCA-4* Konety, Nguyen et al 2000 
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BLCA-4 BLCA-4* Konety, Thu-Suong et al 
2000 
BLCA-4 BLCA-4* Myers-Irvin, Landsittel et al 
2005  
BLCA-4 BLCA-4* Shiff, Veltri et al. 2006 
BTA Complement_factor_H_related_protein*  Blumenstein, Ellis et al. 
1999  
BTA 
Complement_factor_H_related protein* 
Chautard, Daver et al 2000 
BTA 
Complement_factor_H_related_protein* 
Gutiérrez Baños , Martín 
García  et al 1998 
BTA 
Complement_factor_H_related_protein* 
Gutiérrez Baños , Martín 
García  et al 1998 
BTA 
Complement_factor_H_related_protein* 
Heicappell, Wettig et al. 
1999 
BTA 
Complement_factor_H_related_protein* 
Heicappell, Müller et al. 
2000 
BTA 
Complement_factor_H_related_protein* 
Irani,Desgrandchamps et al 
1999 
BTA Complement_factor_H_related_protein* 
Kirillos, McDermott et al 
1997 
BTA Complement_factor_H_related_protein* 
Khaled, Abdel-Salam et al 
2001 
BTA 
Complement_factor_H_related_protein* 
Nasuti, Gomella et al. 1999 
BTA 
Complement_factor_H_related_protein* 
Raitanen, Kaasinen et al. 
2001  
BTA 
Complement_factor_H_related_protein* 
Raitanen, Hellström et al. 
2001 
BTA 
Complement_factor_H_related_protein* 
Takashi, Schenck et al. 1999 
BTA Complement_factor_H_related_protein* Yogi, Ikeuchi et al. 1991 
BTA Complement_factor_H_related_protein* 
Gomez, Rodriguez et al, 
2002 
BTA Complement_factor_H_related_protein* Quek, Chin et al. 2002 
BTA Complement_factor_H_related_protein* Wang, Xu et al. 1999 
BTA Complement_factor_H_related_protein* Miyanaga, Akaza et al. 1997 
BTA Complement_factor_H_related_protein* 
The United Kingdom and 
Eire Bladder Tumour 
Antigen Study Group 1997 
BTA  NMP22  NUMA1 Complement_factor_H_related_protein* Gutiérrez Baños, Rebollo 
Rodrigo et al. 2000 
BTA Complement_factor_H_related_protein* Rodríguez Martínez, Escaf 
Barmadah et al. 2000 
BTA, Survivin Complement_factor_H_related_protein* BIRC5 Davies, Chen et al. 2005 
BTA, UBC Complement_factor_H_related_protein* KRT8 KRT18 Babjuk, Soukup et al. 2008 
BTA, Urinary Bladder 
cancer antigen 
Complement_factor_H_related_protein* KRT8 KRT18 Hazzaa, Elashry et al 2010, 
BTA, Urinary Bladder 
cancer antigen 
Complement_factor_H_related_protein* KRT8 KRT18 Vlahou, Giannopoulos et al. 
2004 
BTA, NMP22, Survivin, 
CD44, VEGF 
NUMA1 Complement_factor_H_related_protein* BIRC5 CD44 VEGF* Sun, He et al. 2006 
BTA 
Complement_factor_H_related_protein* 
Krupski, Moskaluk et al 
2000 
BTA 
Complement_factor_H_related_protein* 
Mattioli, Seregni et al. 2000 
CA 19-9 CA19-9* Vestergaard, Wolf et al. 
1998 
CA19-9 CA19-9* Noto, Fujime et al. 1997 
CA19-9 CA19-9* Pal, Roy et al. 2011 
CA19-9 CA19-9* Roy, Dasgupta et al. 2013 
CA19-9 
CA19-9* 
Chuang & Liao 2004 
CA19-9, 
Carcinoembryonic 
Carcinoembryonic_antigen* Cicigoi, Rocca Rossetti et al. 
1986 
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antigen 
CA19-9, 
Carcinoembryonic 
antigen (CEA), Tissue 
polypeptide antigen 
(TPA) 
CA19-9* Carcinoembryonic_antigen*  Tissue_polypeptide_antigen*  Casetta, Piana et al. 1993 
CA19-9, DU-PAN-2 CA19-9* DUPAN2* Nagao, Itoh et al. 2007 
Calreticulin CALR Kageyama, Isono et al. 2004 
Calreticulin CALR Kageyama, Isono et al. 2009 
Calreticulin annexin A2 
annexin A3 CALR ANXA2 ANXA3 Lu, Lin et al. 2014 
Calreticulin, Catechol-o-
methyltransferase, γ-
synuclein, BTA 
CALR COMT SNCG Complement_factor_H_related_protein* 
Iwaki, kageyama et al 2004 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Colleen, Ek et al 1979 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Coombers, Hall et al. 1975 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Saied, El-Metenawy et al. 
2007 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Wahren, Edsmyr et al. 1975 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Wahren & Edsmyr 1978 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Wahren, Nilsson et al. 1982 
Carcinoembryonic 
antigen  
Carcinoembryonic_antigen* James, Alroy et al. 1980 
Carcinoembryonic 
antigen  
Carcinoembryonic_antigen* Nilsson, Wahren et al. 1982 
Carcinoembryonic 
antigen (CEA)  
Carcinoembryonic_antigen* Nevile, Nery et al 1973 
Carcinoembryonic 
antigen (CEA) /p  +IgG, 
IgA and IgM /p  
Carcinembryonic_antigen* Immunoglobulins* Huland, Otto et al. 1983 
Carcinoembryonic 
antigen (CEA), Ferritin, 
Tissue polypeptide 
antigen (TPA) 
Carcinoembryonic_antIgen* ferritin* tissue_polypeptide_antigen* Halim, el-Ahmady et al. 
1992 
Carcinoembryonic 
antigen FDP 
Carcinoembryonic_antigen* FDP Wajsman, Merrin et al. 
1975 
Cathepsin B CTSB Eiján, Sandes et al 2000 
Cathepsin B CTSB Kotaska, Dusek et al. 2012  
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Fraser, Ravry et al. 1975 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Gadja, Tyloch et al. 1995 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Guinan, McKiel et al.  1978 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Ionescu, Romas et al. 1976 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Jakse, Rauschmeier et al. 
1983 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Klippel, Axt et al. 1983 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Korsetn, Persijn et al. 1976 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Murphy, Vandevoord et al 
1977 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Oshiumi, Yagi et al. 1978  
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Oshiumi, Yagi et al. 1979 
Carcinoembryonic 
antigen 
Carcinoembryonic_antigen* Tailly, Cornelissen et al. 
1983 
Carcinoembryonic Carcinoembryonic_antigen* 
Zimmerman, Wahren et al. 
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antigen 1980 
CEA & TPA Carcinoembryonic_antigen* tissue_polypeptide_antigen* Stefanović, Mitić-Zlatković 
et al. 1999 
CEA, TPA and CA 19-9 Carcinoembryonic_antigen* tissue_polypeptide_antigen* CA19-9* Tizzani, Cassetta et al. 1987 
Chorionic 
Gonadotropin(CG), 
gonadotropin* Iles, Jenkins et al. 1989  
Chorionic 
Gonadotropin(CG), 
gonadotropin* Iles, Persad et al. 1996 
Chorionic 
Gonadotropin(CG), 
Chorionic Gonadotropin 
β-Subunit [GCβ](Core 
fragment as well in 
Urine) 
gonadotropin* Hotakainen, Haglund et al. 
2002 
Clusterin CLU Stejskal & Fiala 2006 
CXCL1 CXCL1 Kawanishi, Matsui et al. 
2008 
Cyfra 21-1 KRT19 El-Ahmady, Halim et al. 
1999 
Cyfra 21-1 KRT19 Nisman, Yutkin et al 2009 
Cyfra 21-1 KRT19 Senga, Kimura et al 1996 
Cyfra 21-1 UBC TPA 
NMP22 
KRT8 KRT18 KRT19 NUMA1 Tissue_polypeptide_antigen* Sánchez-Carbayo, Herrero 
et al. 1999 
CYFRA 21-1, VEGF KRT19 VEGF* Bian and Xu 2007 
CYFRA21-1  KRT19 Dittadi, Barioli et al 1996 
CYFRA21-1  KRT19 Pariente, Bordenave et al 
1997 
CYFRA21-1 FDP NMP22 
UBC KRT19 FGA&FGB NUMA1 KRT8 KRT18 Jeong, Park et al 2012 
CYP1A1 CYP1A1 Dörrenhaus,Müller et al 
2007 
Cystatin B CSTB  Feldman, Banyard et al. 
2009 
cytokeratin cytokeratin* Basta, Attallah et al. 1988 
Cytokeratin cytokeratin* Helmy, Seddek et al. 1991 
D-dimer, IL-6, IL-8, sFAS, 
VEGF, BTA, NMP22  
FGA&FGB IL6 CXCL8 FAS VEGF* Complement_factor_H_related_protein* 
NUMA1 
Abogunrin, O’Kane et al 
2012 
DEK DEK Datta, Adelson et al. 2011 
E-Cadherin CDH1  Banks, Porter et al. 1995 
E-Cadherin CDH1  Protheroe, Banks et al 1999 
E-cadherin CDH1  Shi, Laudon et al. 2008 
EGFR, EpCAM EGFR EpCAM  Bryan, Regan et al. 2015 
EpCAM EpCAM Bryan, Shimwell et al. 2014 
Epidermal growth factor 
(EGF) 
EGF Messing and Murphy-
Brooks 1994 
epithelial membrane 
antigen, NMP52 MUC1 NMP52 Attallah, El-Far et al. 2015 
Fas FAS Yang, Li et al 2013 
FDP, NMP22, BTA FGA&FGB NUMA1 Complement_factor_H_related_protein* Oeda and Manabe 2001) 
Ferritin 
,Carcinoembryonic 
antigen (CEA)  Beta-2 
Microglobulin 
Ferritin* Carcinoembryonic_antigen* B2M Ohashi, Tohjoh et al. 1983  
Fibronectin FN1 Wunderlich, Reichelt et al. 
2001 
FGB, APOE, Alpha-1-
antitrypsin and LRG1 
FGB APOE LRG1 SERPINA1 Lindén, Lind et al. 2012 
Fibronectin FN1 Eissa, Zohny et al 2010 
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Fibronectin FN1 Malmstrom, Larson et al 
1993 
Fibronectin FN1 Ménendez, Fernández-Suárez et al 2005 
Fibronectin, CK18 FN1 KRT18 Sánchez-Carbayo, Urrutia et 
al. 2000 
glutathione S-transferase 
P1 
GSTP1 Lafuente, Rodriguez et al. 
1998 
Heparin-binding 
epidermal growth factor–
like growth factor (HB-
EGF) ,Epidermal growth 
factor (EGF) 
EGF HBEGF Keay, Zhang et al. 2001 
HIP/PAP REG3A Nitta,Konishi et al 2012 
Histone H2B  NIF-1 Histone_H2B* ZNF335 Frantzi, Zoidakis et al. 2013 
HSP60, HSP70, HSP90, 
Interferon-γ, Tumour 
necrosis factor-α, 
Tumour growth factor-β, 
IL-2, IL-4, IL-5, IL-6, IL-8, 
IL-10, IL-13 
HSPD1 HSP70 HSP90AA1 IFNG TNF TGFB IL1B IL2 IL4 IL5 IL6 CXCL8 IL10 IL13 Margel, Pevsner-Fischer et 
al. 2011 
HtrA1 HTRA1 Lorenzi, Lorenzi et al. 2013 
ICAM1 ICAM1 Chow, Cheng et al. 1998 
ICAM1 ICAM1 Shi, Goya et al 1998 
IL-11 IL11  Wu, Tao et al. 2013 
IL-18, IL-2, IFN-gamma, 
IL-12, IL-4 
IL18 IFNG IL12 IL4  Eto, Koga et al. 2005 
IL-1b, IL1B Martins, Darlin et al. 1994 
IL-1b, IL- 2, IL- 6, IL- 8, IL-
10, IL-12, TNF-a, and IFN-
gamma 
IL1B IL2 IL6 CXCL8 IL10 IL12 TNFA IFNG Watanabe, Matsuyama et 
al. 2003 
IL-1b, IL- 2, IL- 6, IL- 8, IL-
10, IL-12, TNF-a, IFN-
gamma,Intercellular 
adhesion molecule-1 
(ICAM-1) 
IL1B IL2 IL6 CXCL8 IL10 IL12A TNFA IFNG ICAM1 Jackson, Alexandroff et al. 
1995 
IL2, IL6, IL8, TNF Alpha, 
CYFRA 21-1, NMP22 
IL2 IL6 CXCL8 TNFA NUMA1 KRT19  Sanchez-Carbayo, Urrutia et 
al. 2001 
Il-6, IL-10  IL6 IL10 Cai, Mazzoli, et al 2012 
IL-6, IL-8, VEGF IL6 CXCL8 VEGF* Reid, Stevenson et al. 2012 
IL-8 CXCL8 Sheryka, Wheeler et al 2003 
IL-8, MMP-9 and 10, PAI-
1, VEGF, ANG, CA9 APOE IL-8 MMP9 MMP10 PAI-1 VEGF* ANG CA9  APOE 
Rosser, Ross et al. 2013 
IL-8, MMP9, MMP10, 
SDC1, CCL18, PAI-1, 
CD44, VEGF, ANG, 
CA9,A1AT,OPN, PTX3, 
APOE 
CXCL8 MMP9 MMP10 SDC1 CCL18 SERPINE1 CD44 VEGF* ANG CA9 
SERPINA1 SPP1 PTX3 APOE 
Goodison, Chang et al. 2012 
IL-8, MMP9, Syndecan, 
BTA 
CXCL8 MMP9 SDC1 Complement_factor_H_related_protein* Urquidi, Chang et al. 2012 
IL-8, MMP9, VEGFA CXCL8 MMP9 VEGFA Rosser, Dai et al. 2014 
Insulin-like growth factor 
2 
IGF2 Watson, Burling et al. 2009 
intercellular adhesion 
molecule-1, NMP 22, 
Monocyte 
chemoattractant protein-
1. 
ICAM1 NUMA1 CCL2 Parekattil, Fisher et al. 2003 
Interleukin-2 IL2 Fleischmann, Toossi et al. 
1989  
Keratin (CK1K10 
antibody) 
cytokeratin* Attallah, Helmi et al. 1991 
Laminin P1 Laminin* Abou Farha, Meneheers et 
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al. 1993 
Midkine, HAI-1, ULBP2 MDK SPINT1 ULBP2 Shimwell, Bryan et al. 2013 
MMP1, MMP10 MMP1 MMP10 Du, Lin et al. 2014 
MMP2, MMP9 MMP2  MMP9 Gerhards, Jung et al. 2001 
MMP2,  MMP9,  
Cathepsin B, UPA 
MMP2 MMP9 CTSB PLAU Sier, Casetta et al. 2000 
MMP2, MMP9, 
Fibronectin 
MMP2 MMP9 FN1  Saito, Kimoto et al. 2005 
MMP2, MMP9, 
MMP2/NGAL, 
MMP9/TIMP, ADAMTS 
MMP2 MMP9 ADAMTS TIMP1 NGAL Mohammed, Seleim et al. 
2013 
MMP2, MMP9, NGAL MMP2 MMP9 LCN2 Fernández, Wszolek  et al 2009 
MMP2, MMP9, TIMP-2 MMP2 MMP9 TIMP2  Eissa, Ali-Labib et al. 2007 
MMP2, MMP9, UBC, TPS, 
NMP22 
MMP2 MMP9 KRT8 KRT18 NUMA1  tissue-polypeptide-specific antigen* Di Carlo, Terracciano et al. 
2006 
MMP3, MMP9 MMP3 MMP9 El-Sharkawi, El Sabah et al. 
2014 
MMP7 MMP7 Jäger, Tschirdewahn et al. 
2013  
MMP7 MMP7 Szarvas, Singer et al. 2011  
MMP9 MMP9 Eissa, Labib et al 2003 
MMP9 MMP9 Offersen, Knap et al. 2010 
BTA Complement_factor_H_related_protein* Thomas, Leyh et al 1999 
MMP-9, MMP-2, 
ADAMTS 7, MMP-
9/NGAL complex, 
MMP9/TIMP complex  
and MMP-9 dimer 
MMP9 MMP2 ADAMTS7 NGAL TIMP1 Roy, Louis et al. 2008 
MUC1 MUC1 Xiang, Zhou et al. 2005 
nicotinamide N-
methyltransferase 
NNMT Sartini, Muzzonigro et al. 
2013 
NMP2, BTA NUMA1 Complement_factor_H_related_protein* Abd El Gawad, Moussa et 
al. 2005 
NMP22 NUMA1 Arora, Sarunban et al. 2010 
NMP22 NUMA1 Atsu, Ekici et al. 2002 
NMP22 NUMA1 Akaza, Miyanaga et al. 
1997a 
NMP22 NUMA1 Akaza, Miyanaga et al. 
1997b 
NMP22 NUMA1 Casella, Huber et al 2000 
NMP22 NUMA1 Chahal, Darshane et al. 
2001 
NMP22 NUMA1 Chang, Wu et al. 2004 
NMP22 NUMA1 Hutterer, Karakiewicz et al. 
2008 
NMP22 NUMA1 ippe, Pandrangi et al. 1999 
NMP22 NUMA1 Kapila, Kehinde et al 2008 
NMP22 NUMA1 Kumar, Kumar et al. 2006 
NMP22 NUMA1 Kundal, Pandith et al 2010 
NMP22 NUMA1 Landman, Change et al 1998 
NMP22 NUMA1 Lahme,  Bichler et al 2000 
NMP22 NUMA1 Lekili, Sener et al. 2004 
NMP22 NUMA1 Menendez, Filella et al 2000 
NMP22 NUMA1 Moonen, Kiemeney et al. 
2005 
NMP22 NUMA1 O’Sullivan, Sharples et al 
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2012 
NMP22 
NUMA1 
Oge, Atsu et al. 2001 
nmp22 NUMA1 Onal, Han et al. 2015 
NMP22 NUMA1 Paoluzzi,Cuttano et al 1999 
NMP22 NUMA1 Pérez García, Escaf 
Barmadah et al 2000 
NMP22 NUMA1 Ponsky, Sharma et al. 2001 
nmp22 
NUMA1 
Raina, Pahlajani et al. 2008 
NMP22 NUMA1 Sagnak, Ersoy et al. 2011 
NMP22 
NUMA1 Sánchez-Carbayo, Herrero 
et al 1999 
NMP22 NUMA1 Serreta, Lo Presti et al 1998 
NMP22 NUMA1 Serretta, Presti et al 1998 
NMP22 
NUMA1 
Shariat, Savage et al. 2011 
NMP22 NUMA1 Shariat, Zippe et al. 2005 
NMP22 NUMA1 Schlake, Crispen et al. 2012 
NMP22 NUMA1 Soloway, Briggman et al 1996 
NMP22 NUMA1 Srivastava, Arora et al. 2012 
NMP22 NUMA1 Thomas, Leyh et al 1999 
NMP22 
NUMA1 Todenhöfer, Hennenlotter 
et al. 2014 
NMP22 
NUMA1 
Lotan, Elias et al. 2009 
NMP22 
NUMA1 
Lotan, Capitanio et al. 2009 
NMP22 
NUMA1 
Ueda, Kawaguchi et al. 2009 
NMP22 NUMA1 Rodríguez , Justo et al. 2008 
NMP22 NUMA1 Mansoor, Calam et al. 2008 
NMP22 NUMA1 Ihm, Kim et al. 2007 
NMP22 NUMA1 Chen, Han et al.  2007 
NMP22 NUMA1 
Hautmann, Eggers et al.  
2007 
NMP22 NUMA1 
Fatela-Cantillo, Fernandez-
Suarez et al 2007 
NMP22 NUMA1 Darenkov, Perlin et al. 2006 
NMP22 NUMA1 Xin, You et al. 2006 
NMP22 NUMA1 
Kitukawa, Yamamoto et. 
2006 
NMP22 NUMA1 
Yokoyama, Sekigawa et al. 
2004 
NMP22 NUMA1 Su, Yang et al. 2003 
NMP22 NUMA1 
Perez-Garcia, Eyo et al. 
2002 
NMP22 NUMA1 
Miyoshi, Matsuzaki et al. 
2001 
NMP22 NUMA1 Zippe, Pandrangi et al. 1999 
NMP22 NUMA1 Zippe, Pandrangi et al. 1999 
NMP22 NUMA1 Lahme, Bichler et al. 2001 
NMP22  NUMA1 Stampfer,Carpinito et al 1998 
NMP22 BTA NUMA1  Complement_factor_H_related_protein* Casetta, Gontero et al. 2000 
NMP22 BTA  NUMA1  Complement_factor_H_related_protein* Friedrich, Hellstern et al. 
2002 
NMP22 BTA  NUMA1  Complement_factor_H_related_protein* Friedrich, Hellstern et al. 
2003 
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NMP22, BTA, Basic 
Fetoprotein(BFP) 
NUMA1 BFP* Complement_factor_H_related_protein Miyanaga, Akaza et al. 2003 
NMP22, cytokeratin-18 NUMA1 KRT18 Song, Du et al. 2009 
NMP22 MCM5 NUMA1 MCM5 Kelly, Dudderidge et al. 
2012 
NMP22, BTA NUMA1 Complement_factor_H_related_protein* Abbate, D'Introno et al. 
1998 
NMP22, BTA 
NUMA1 Complement_factor_H_related_protein* 
Miyake, Nakai et al 2014 
NMP22, Fibronectin NUMA1 FN1 Eissa, Swellam et al 2002 
NMP22,BTA  NUMA1 Complement_factor_H_related_protein* Serretta, Pomara et al 2000 
NMP22,E-cadherin, 
cathepsin D 
NUMA1 CDH1 CTSD  Salama, Selem et al. 2012 
NMP22, BTA  NUMA1 Complement_factor_H_related_protein* Bhuiyan, Akhter et al. 2003 
NMP22, BTA  NUMA1 Complement_factor_H_related_protein* Sharma, Zippe et al 1999 
NMP22, Urinary Bladder 
Cancer test(UBC) 
NUMA1 KRT8 KRT18 Kibar, Goktas et al. 2006 
NMP52 NMP52* Attalah, Sakr et al. 2005 
Oncofetal fibronectin FN1  Alías-Melgar, Neave-
Sánchez et al. 2013 
Orosomucoid(ORM), 
zinc-alpha2-
glycoprotein(ZAG) 
ORM1 AZGP1 Irmak, Tilki et al. 2005 
PAI-1, BTA, CD44, CCL18 SERPINE1 CD44 CCL18 Complement_factor_H_related_protein* Urquidi V, Kim et al 2012 
Plasminogen  Activator 
Inhibitor type I (PAI-1) 
SERPINE1  Becker, Szarvas et al. 2010 
Prothymosin-alpha PTMA Tzai, Tsai et al. 2006 
Pro-u-PA PLAU  Lin , Tsui et al. 2006 
Psoriasin 
S100A7 
Celis, Rasmussen et al. 1996 
sCD14 CD14 Jackson, Lien et al. 1997 
Serine/threonine-protein 
kinase PLK2 
PLK2 Tan, Chen et al. 2010 
SH3BGRL3 SH3BGRL3 Chiang, Pan et al. 2015 
Soluble carbonic 
anhydrase IX (s-CAIX) 
CA9 Hyrsl, Zavada et al. 2009 
Soluble E-Cadherin CDH1 Shariat, Matsumoto et al. 
2005 
Soluble intercellular 
adhesion molecule-1 
ICAM1 Aboughalia 2006 
Soluble Met (sMet) MET McNeil, Sorbellini et al. 
2014 
survivin BIRC5 Abd El-Halim, El-Shafie et al. 
2014 
Survivin BIRC5  Hausladen, Wheeler et al. 
2003 
Survivin BIRC5 Li, Wang et al 2013 
Survivin BIRC5 Srivastava, Singh et al. 2013 
Survivin BIRC5 
Sharp, Hausladen et al. 
2002 
Survivin, NMP22 BIRC5 NUMA1  Shariat, Casella et al. 2004 
Survivin,  CYFRA 21-1 BIRC5 KRT19 Ohsawa, Nishimura et al. 
2004 
Syndecan-1 SDC1 Miyake, Lawton et al. 2014 
TACSTD2 TACSTD2 Chen, Lai et al 2012 
Tenascin C( B and C 
domains) 
TNC Richter, Tost et al. 2009  
Tenascin-C TNC Gecks, Junker et al. 2011 
Tenascin-C TNC Guan, Zeng et al. 2014 
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TGFα, VEGF TGFA VEGFA  Hameed and el-Metwally 
2008 
Thromboxane receptor TBXA2R Moussa et al. 2011 
TIMP-2 survivin TIMP2 BIRC5 Eissa, Shabayek et al. 2010 
Tissue factor F3 Lwaleed, Francis et al. 2000 
Tissue Polypeptide 
Antigen 
Tissue_polypeptide_antigen* Costello and Kumar 1985 
Tissue polypeptide 
antigen (TPA) 
Tissue_polypeptide_antigen* Carbin, Ekman et al. 1989 
Tissue polypeptide 
antigen (TPA) 
Tissue_polypeptide_antigen* Mack, Scheiber et al. 1987 
Tissue polypeptide 
antigen (TPA)  
Tissue_polypeptide_antigen* Kumar, Costello et al. 1981 
Tissue polypeptide 
antigen (TPA), HER-
2/neu(EGF), Urokinase-
type Plasminogen 
Activator Receptor 
(uPAR) ,TP53 Mutation 
Tissue_polypeptide_antigen* EGF PLAUR Ecke, Schlechte et al. 2005 
tissue polypetide specific 
antigen 
tissue-polypeptide-specific antigen* Boman, Hedelin et al. 2001 
tissue-polypeptide-
specific antigen (TPS) 
tissue-polypeptide-specific antigen* Sánchez-Carbayo, Urrutia, 
et al 2000 
tissue-polypeptide-
specific antigen (TPS) 
tissue-polypeptide-specific antigen* Yao, Chang et al. 1995 
UBC KRT8 KRT18 Hedelin, Jonsson et al. 2006 
UBC KRT8 KRT18 Heicappell, Schostak et al. 
2000 
UBC KRT8 KRT18 Sánchez-Carbayo, Herrero 
et al 1999 
UBC 
KRT8 KRT18 
Gacci, Serni et al. 2006 
UBC CYFRA 21-1 NMP22 KRT8 KRT18 KRT19 NUMA1 Sánchez-Carbayo, Urrutia et 
al. 2001 
Urinary bladder 
carcinoma antigen (UBC), 
Urine tumor-associated 
trypsin inhibitor(TATI), 
CYFRA 21-1 
KRT8 KRT18 KRT19 SPINK1 Gkialas, Papadopoulos et al 2008 
Urinary gonadotropin 
peptide (UGP) gonadotrophin* El-Ahmady, Halim et al 1996 
Urinary sFas FAS Srivastava, Singh et al 2014 
Urinary sFas, NMP22 FAS NUMA1 Svatek, Herman et al. 2006 
Urine tumor-associated 
trypsin inhibitor(TATI), 
NMP22 
SPINK1 NUMA1  Shariat, Herman et al. 2005 
Urine tumour-associated 
trypsin inhibitor(TATI) 
SPINK1 Kelloniemi, Rintala et al. 
2003 
Urokinase-type 
Plasminogen 
Activator(uPA),Urokinase
-type Plasminogen 
Activator Receptor 
(uPAR)  
PLAU PLAUR Casella, Shariat et al. 2002 
Urokinase-type 
Plasminogen 
Activator(uPA),Urokinase
-type Plasminogen 
Activator Receptor 
(uPAR), NMP22  
PLAU PLAUR NUMA1 Shariat, Casella et al. 2003 
Uroplakin Uroplakin* Lai, Ye et al. 2010 
VEGF VEGF* Crew, O’Brien et al 1999 
VEGF VEGF* Jeon, Lee et al 2001 
VEGF, angiogenin VEGF* ANG Urquidi, Goodison, et al 2012 
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Vitamin D binding 
protein GC Li, Chen et al 
Fibronectin FN1 
Hegele, Heidenreich et al. 
2003  
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